A Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Non-small Cell Lung Cancer - AEGEAN

Study identifier:D9106C00001

ClinicalTrials.gov identifier:NCT03800134

EudraCT identifier:2018-002997-29

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine

Sex

All

Actual Enrollment

826

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 06 Dec 2018
Primary Completion Date: 10 Nov 2022
Estimated Study Completion Date: 11 Sept 2028

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria